References
- Hjermann I, Byre K V, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981; 11: 1303–10
- Kjeldsen S E, Flaaten B, Eide I, Helgeland A, Leren P. Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension. Scand J Clin Lab Invest 1982; 42: 217–23
- van Brummelen P, Jie K, van Zwieten P A. Alpha-adrenergic receptors in human blood vessels. Br J Clin Pharmac 1986; 21: 33S–39S
- Cubeddu L X. New alpha-1-adrenergic receptor antagonists for the treatment of hypertension: Role of vascular alpha receptors in the control of peripheral resistance. Am Heart J 1988; 116: 133–62
- Lund-Johansen P, Omvik P, Haugland H. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise. Br J Clin Pharmac 1986; 21: 45S–54S
- Rouffy J, Jaillard J. Etude comparative des effects de la prazosine et de l'atenolol sur lea lipides plasmatigues de patients hypertendu. Rev Med Interne 1985; 6: 77–81
- Cox D A, Leader J P, Milwon J A, Singleton W. The antihypertensive effects of doxazosin: a clinical overview. Br J Clin Pharmacol 1986; 21: 83S–90S
- Frick M H, Halttunen P, Huttunen M, Porsti P, et al. A long-term double blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. Br J Clin Pharmac 1986; 21: 55S–62S
- Lehtonen A, Hirmane P, Saraste M, Niitymaki K, Marniemi J. Double blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. Br J Clin Pharmac 1986; 21: 77S–81S
- Nash D T, Schonfeld G, Reeves R L, Black H, Weidler D J. A double blind parallel trial to assess the efficacy of doxozasin, atenolol and placebo in patients with mild to moderate systemic hypertension. Am J Cardiol 1987; 59: 87G–90G
- Ott P, Storm T L, Krusell L R, Jensen H, Badskjaer J, et al. Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension. Am J Cardiol 1987; 59: 73G–77G
- Torvik D, Madsbu H P. Multicenter 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmac 1986; 21: 69S–75S
- Trost B N, Madsbu H P. Multicenter 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmac 1986; 21: 99G–104G
- Leenen F HH, Smith D L, Farkas R M, Reeves R A, Marguez-Julio A. Vasodilators and regression of left ventricular hypertrophy. Am J Med 1987; 82: 969–78
- Castelli W P, Anderson K. A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med 1986; 80: 23–32
- Sacks F M, Dzau V J. Adrenergic effects on plasma lipoprotein metabolism. Am J Med 1986; 80: 71–81
- Leren T P. Doxazosin increases low-density lipoprotein receptor activity. Acta Pharmacol Toxicol 1985; 56: 269–72